Intra-Cellular Therapies, Inc. (ITCI)
NASDAQ: ITCI · Real-Time Price · USD
128.60
+0.06 (0.05%)
Feb 21, 2025, 4:00 PM EST - Market closed
Intra-Cellular Therapies Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | - | -139.67 | -256.26 | -284.13 | -227.01 | |
| Depreciation & Amortization | - | 0.53 | 0.66 | 0.53 | 0.53 | |
| Loss (Gain) From Sale of Investments | - | -8.4 | 0.45 | -4.08 | -0.65 | |
| Stock-Based Compensation | - | 52.92 | 43.1 | 34.48 | 24.33 | |
| Change in Accounts Receivable | - | -38.83 | -55.03 | -9.39 | -10.77 | |
| Change in Inventory | - | -26.35 | -15.97 | -0.89 | -7.06 | |
| Change in Accounts Payable | - | 1.06 | 1.7 | 3.19 | -1.92 | |
| Change in Other Net Operating Assets | - | 34.54 | 11.17 | 0.74 | -7.8 | |
| Operating Cash Flow | - | -124.2 | -270.19 | -259.54 | -230.07 | |
| Capital Expenditures | - | -0.27 | -0.78 | -0.33 | -0.27 | |
| Investment in Securities | - | 105.81 | -127.6 | 280.67 | -480.03 | |
| Investing Cash Flow | - | 105.54 | -128.37 | 280.34 | -480.3 | |
| Issuance of Common Stock | - | 17.81 | 455.16 | 11.52 | 664.18 | |
| Financing Cash Flow | - | 17.81 | 455.16 | 11.52 | 664.18 | |
| Net Cash Flow | - | -0.85 | 56.6 | 32.32 | -46.19 | |
| Free Cash Flow | - | -124.47 | -270.96 | -259.87 | -230.34 | |
| Free Cash Flow Margin | - | -26.80% | -108.25% | -310.10% | -1009.69% | |
| Free Cash Flow Per Share | - | -1.30 | -2.88 | -3.20 | -3.27 | |
| Cash Income Tax Paid | - | 0.16 | 0.01 | 0.01 | 0 | |
| Levered Free Cash Flow | - | -28.97 | -180.85 | -150.04 | -148.8 | |
| Unlevered Free Cash Flow | - | -28.97 | -180.85 | -150.04 | -148.8 | |
| Change in Net Working Capital | 54.9 | -17.46 | 59.06 | 6.18 | 28.87 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.